Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KEM YENAL

Allopathic & Osteopathic Physicians Family Medicine

NPI
1215913868
CMS profile
235822
Location
PHILA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$2,304.13

65 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,304.13 65

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KEM YENAL

NPI 1215913868 · CMS profile ID 235822

Allopathic & Osteopathic Physicians / Family Medicine

PHILA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1215913868?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KEM YENAL, NPI 1215913868, CMS profile ID 235822. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1215913868?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). KEM YENAL, NPI 1215913868, CMS profile ID 235822. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1215913868?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
KEM YENAL, NPI 1215913868, CMS profile ID 235822, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1215913868?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

65 matching records · $2,304.13 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 65 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–65 of 65.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $23.1801/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893249283 CMS
ITI, Inc. $21.5401/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945745293 CMS
ABBVIE INC. $100.9801/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893249281 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $11.9801/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887597745 CMS
Novo Nordisk Inc $20.3001/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898620143 CMS
Lilly USA, LLC $14.7301/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918158887 CMS
Lilly USA, LLC $14.9101/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918102217 CMS
Merck Sharp & Dohme LLC $13.8401/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944072377 CMS
Novo Nordisk Inc $16.9601/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899438999 CMS
Nabriva Therapeutics, plc $14.9101/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 961089379 CMS
Otsuka America Pharmaceutical, Inc. $18.2601/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929354691 CMS
ABBVIE INC. $13.2001/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893249279 CMS
Bayer HealthCare Pharmaceuticals Inc. $14.4501/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930095773 CMS
Xeris Pharmaceuticals, Inc. $23.0501/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946482111 CMS
Novo Nordisk Inc $15.2401/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899438995 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $10,147.38 243
PY2020 $969.24 46
PY2021 $2,519.37 75
PY2022 $2,304.13 65
PY2023 $846.79 13
PY2024 $2,864.83 28
PY2025 $546.88 8

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $292,468.81 66
PY2024 Principal investigator $3,931,572.99 136
PY2023 Principal investigator $6,675,430.28 2,716
PY2022 Principal investigator $1,662,724.82 26

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

66 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $100.00 12/23/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252957929
Principal investigator 1 ModernaTX, Inc. $5,844.50 11/24/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252957881
Principal investigator 1 ModernaTX, Inc. $334.04 11/24/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252957901
Principal investigator 1 ModernaTX, Inc. $6,054.54 11/24/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252957903
Principal investigator 1 ModernaTX, Inc. $5,364.50 11/24/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252957905
Principal investigator 1 ModernaTX, Inc. $3,125.28 11/24/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252957907
Principal investigator 1 ModernaTX, Inc. $1,939.08 11/24/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252957909
Principal investigator 1 ModernaTX, Inc. $1,581.68 11/24/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252957913
Principal investigator 1 ModernaTX, Inc. $7,100.24 11/24/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252957915
Principal investigator 1 ModernaTX, Inc. $318.58 11/24/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252957945
Principal investigator 1 ModernaTX, Inc. $5,992.32 11/24/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252957947
Principal investigator 1 ModernaTX, Inc. $2,231.84 11/24/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252957955
Principal investigator 1 ModernaTX, Inc. $473.58 11/24/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252957979
Principal investigator 1 ModernaTX, Inc. $120.01 11/24/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252957981
Principal investigator 1 ModernaTX, Inc. $491.52 11/24/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252957987
Principal investigator 1 ModernaTX, Inc. $469.20 10/27/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252957885
Principal investigator 1 ModernaTX, Inc. $406.62 10/27/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252957887
Principal investigator 1 ModernaTX, Inc. $431.96 10/27/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252957889
Principal investigator 1 ModernaTX, Inc. $122.90 10/27/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252957891
Principal investigator 1 ModernaTX, Inc. $344.90 10/27/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252957923
Principal investigator 1 ModernaTX, Inc. $218.64 10/27/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252957957
Principal investigator 1 ModernaTX, Inc. $171.72 10/27/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252957961
Principal investigator 1 ModernaTX, Inc. $51.64 10/27/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252957973
Principal investigator 1 ModernaTX, Inc. $2,550.00 09/03/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252957899
Principal investigator 1 ModernaTX, Inc. $1,600.00 09/03/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252957917
Principal investigator 1 ModernaTX, Inc. $1,500.00 09/03/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252957949
Principal investigator 1 ModernaTX, Inc. $2,250.00 09/03/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252957953
Principal investigator 1 ModernaTX, Inc. $1,750.00 09/03/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252957983
Principal investigator 1 ModernaTX, Inc. $1,500.00 08/06/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252957883
Principal investigator 1 ModernaTX, Inc. $500.00 08/06/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252957921
Principal investigator 1 ModernaTX, Inc. $1,200.00 07/23/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252957927
Principal investigator 1 ModernaTX, Inc. $2,067.04 07/23/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252957959
Principal investigator 1 ModernaTX, Inc. $132.50 07/23/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252957969
Principal investigator 1 ModernaTX, Inc. $220.00 07/23/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252957971
Principal investigator 1 ModernaTX, Inc. $1,224.32 07/23/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252957991
Principal investigator 1 ModernaTX, Inc. $1,000.00 06/20/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252957895
Principal investigator 1 ModernaTX, Inc. $278.25 06/20/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252957935
Principal investigator 1 ModernaTX, Inc. $935.00 06/20/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252957939
Principal investigator 1 ModernaTX, Inc. $1,350.00 06/20/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252957941
Principal investigator 1 ModernaTX, Inc. $500.00 06/20/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252957977
Principal investigator 1 ModernaTX, Inc. $5,970.79 06/18/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252957993
Principal investigator 1 AstraZeneca Pharmaceuticals LP $26,700.00 04/02/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185544293
Principal investigator 1 ModernaTX, Inc. $3,703.38 04/01/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252957999
Principal investigator 1 ModernaTX, Inc. $998.00 03/24/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252957925
Principal investigator 1 ModernaTX, Inc. $600.00 03/24/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252957965
Principal investigator 1 ModernaTX, Inc. $1,200.00 03/24/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252957967
Principal investigator 1 PFIZER INC. $3,698.95 03/22/2025 Non-covered Recipient Entity
Dynamed Philadelphia LLC
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1228853438
Principal investigator 1 ModernaTX, Inc. $1,920.00 03/10/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252957919
Principal investigator 1 ModernaTX, Inc. $900.00 03/07/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252957975
Principal investigator 1 ModernaTX, Inc. $1,113.00 03/07/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252958001
Principal investigator 1 ModernaTX, Inc. $13,005.63 03/03/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252957931
Principal investigator 1 ModernaTX, Inc. $110.00 02/19/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252957943
Principal investigator 1 PFIZER INC. $12,082.60 02/14/2025 Non-covered Recipient Entity
Dynamed Philadelphia LLC
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1228837323
Principal investigator 1 ModernaTX, Inc. $6,680.76 02/12/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252957911
Principal investigator 1 ModernaTX, Inc. $331.25 02/12/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252957933
Principal investigator 1 ModernaTX, Inc. $56,994.00 02/12/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252957995
Principal investigator 1 ModernaTX, Inc. $3,818.00 02/12/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252957997
Principal investigator 1 ModernaTX, Inc. $53,813.55 02/07/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252957937
Principal investigator 1 ModernaTX, Inc. $2,625.00 02/03/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252957893
Principal investigator 1 ModernaTX, Inc. $68.69 01/29/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252957951
Principal investigator 1 ModernaTX, Inc. $8,914.44 01/29/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252957963
Principal investigator 1 ModernaTX, Inc. $2,999.36 01/29/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252957985
Principal investigator 1 ModernaTX, Inc. $8,207.04 01/29/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252957989
Principal investigator 1 AstraZeneca UK Limited $10,822.00 01/15/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment No dispute reported 06/30/2026 1185544291
Principal investigator 1 ModernaTX, Inc. $278.25 01/15/2025 Non-covered Recipient Entity
DYNAMED PHILADELPHIA LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252957897
Principal investigator 1 PFIZER INC. $1,067.72 01/15/2025 Non-covered Recipient Entity
Dynamed Philadelphia LLC
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1228853001